Inflammasome: Cancer's friend or foe?

Michela Terlizzi, Vincenzo Casolaro, Aldo Pinto, Rosalinda Sorrentino

Research output: Contribution to journalArticle

Abstract

High serum concentrations of IL-1β and IL-18 are correlated to malignancies with low-rate survival from the time of diagnosis. The multimeric complex of the inflammasome is responsible for IL-1β/IL-18 synthesis/release. A number of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli can provide signals for inflammasome activation in cancer. These stimuli can behave as tumor promoters via inducing chronic inflammation that, rather than providing a protective response to loss of tissue homeostasis, aberrantly facilitates tumor development. This view is contrasted in animal models of colon cancer in which the activation of some inflammasome complexes is associated with tumor protection. More studies are needed to understand the biology of the inflammasome in cancer and explore its therapeutic potential.

Original languageEnglish (US)
Pages (from-to)24-33
Number of pages10
JournalPharmacology and Therapeutics
Volume143
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Inflammasomes
Interleukin-18
Neoplasms
Interleukin-1
Carcinogens
Colonic Neoplasms
Homeostasis
Survival Rate
Animal Models
Inflammation
Serum

Keywords

  • Carcinogenesis
  • Chronic inflammation
  • Inflammasome
  • Tumor immunology
  • Tumor progression

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Terlizzi, M., Casolaro, V., Pinto, A., & Sorrentino, R. (2014). Inflammasome: Cancer's friend or foe? Pharmacology and Therapeutics, 143(1), 24-33. https://doi.org/10.1016/j.pharmthera.2014.02.002

Inflammasome : Cancer's friend or foe? / Terlizzi, Michela; Casolaro, Vincenzo; Pinto, Aldo; Sorrentino, Rosalinda.

In: Pharmacology and Therapeutics, Vol. 143, No. 1, 2014, p. 24-33.

Research output: Contribution to journalArticle

Terlizzi, M, Casolaro, V, Pinto, A & Sorrentino, R 2014, 'Inflammasome: Cancer's friend or foe?', Pharmacology and Therapeutics, vol. 143, no. 1, pp. 24-33. https://doi.org/10.1016/j.pharmthera.2014.02.002
Terlizzi, Michela ; Casolaro, Vincenzo ; Pinto, Aldo ; Sorrentino, Rosalinda. / Inflammasome : Cancer's friend or foe?. In: Pharmacology and Therapeutics. 2014 ; Vol. 143, No. 1. pp. 24-33.
@article{e092829816e242a89ae5b834b6f66b36,
title = "Inflammasome: Cancer's friend or foe?",
abstract = "High serum concentrations of IL-1β and IL-18 are correlated to malignancies with low-rate survival from the time of diagnosis. The multimeric complex of the inflammasome is responsible for IL-1β/IL-18 synthesis/release. A number of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli can provide signals for inflammasome activation in cancer. These stimuli can behave as tumor promoters via inducing chronic inflammation that, rather than providing a protective response to loss of tissue homeostasis, aberrantly facilitates tumor development. This view is contrasted in animal models of colon cancer in which the activation of some inflammasome complexes is associated with tumor protection. More studies are needed to understand the biology of the inflammasome in cancer and explore its therapeutic potential.",
keywords = "Carcinogenesis, Chronic inflammation, Inflammasome, Tumor immunology, Tumor progression",
author = "Michela Terlizzi and Vincenzo Casolaro and Aldo Pinto and Rosalinda Sorrentino",
year = "2014",
doi = "10.1016/j.pharmthera.2014.02.002",
language = "English (US)",
volume = "143",
pages = "24--33",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Inflammasome

T2 - Cancer's friend or foe?

AU - Terlizzi, Michela

AU - Casolaro, Vincenzo

AU - Pinto, Aldo

AU - Sorrentino, Rosalinda

PY - 2014

Y1 - 2014

N2 - High serum concentrations of IL-1β and IL-18 are correlated to malignancies with low-rate survival from the time of diagnosis. The multimeric complex of the inflammasome is responsible for IL-1β/IL-18 synthesis/release. A number of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli can provide signals for inflammasome activation in cancer. These stimuli can behave as tumor promoters via inducing chronic inflammation that, rather than providing a protective response to loss of tissue homeostasis, aberrantly facilitates tumor development. This view is contrasted in animal models of colon cancer in which the activation of some inflammasome complexes is associated with tumor protection. More studies are needed to understand the biology of the inflammasome in cancer and explore its therapeutic potential.

AB - High serum concentrations of IL-1β and IL-18 are correlated to malignancies with low-rate survival from the time of diagnosis. The multimeric complex of the inflammasome is responsible for IL-1β/IL-18 synthesis/release. A number of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli can provide signals for inflammasome activation in cancer. These stimuli can behave as tumor promoters via inducing chronic inflammation that, rather than providing a protective response to loss of tissue homeostasis, aberrantly facilitates tumor development. This view is contrasted in animal models of colon cancer in which the activation of some inflammasome complexes is associated with tumor protection. More studies are needed to understand the biology of the inflammasome in cancer and explore its therapeutic potential.

KW - Carcinogenesis

KW - Chronic inflammation

KW - Inflammasome

KW - Tumor immunology

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=84898886920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898886920&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.02.002

DO - 10.1016/j.pharmthera.2014.02.002

M3 - Article

C2 - 24518102

AN - SCOPUS:84898886920

VL - 143

SP - 24

EP - 33

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -